Table 3.
Kidney transplant recipients' characteristics.
| BWH kidney TX “NR” (n = 19) | BWH kidney TX “TCMR” (n = 9) | BWH kidney TX “AMR” (n = 8) | VCA (n = 19) | p-value | |
|---|---|---|---|---|---|
| Sex | |||||
| Male | 12 (63%) | 5 (56%) | 7 (88%) | 14 (74%) | *0.73, #0.40, $0.63 |
| Female | 7 (37%) | 4 (44%) | 1 (12%) | 5 (26%) | |
| Age at TX (years, mean ± SD) | 43.4 ± 12.4 | 52.1 ± 16.3 | 36.8 ± 14.2 | 36.9 ± 12.3 | *0.11, #0.01, $0.98 |
| Race | |||||
| White | 14 (74%) | 6 (67%) | 6 (75%) | 19 (100%) | *0.05, #0.03, $0.08 |
| Black | 5 (26%) | 3 (33%) | 2 (25%) | 0 (0%) | |
| Induction agent | |||||
| ATG/Alemtuzumab | 17 (89%) | 7 (78%) | 6 (75%) | 19 (100%) | *0.49, #0.10, $0.99 |
| Basiliximab | 2 (11%) | 2 (12%) | 0 (0%) | 0 (0%) | |
| Unknown | 0 (0%) | 0 (0%) | 2 (25%) | 0 (0%) | |
| Maintenance immunosuppression | |||||
| CNI | 19 (100%) | 8 (89%) | 6 (75%) | 18 (94%) | *0.99, #0.99, $0.20 |
| MMF/MPA | 19 (100%) | 7 (78%) | 6 (75%) | 19 (100%) | *0.99, #0.10, $0.08 |
| Azathioprine | 0 (0%) | 2 (22%) | 1 (12%) | 0 (0%) | *0.99, #0.10, $0.30 |
| Sirolimus/Everolimus | 0 (0%) | 0 (0%) | 2 (25%) | 2 (11%) | *0.49, #0.99, $0.56 |
| Prednisone | 13 (68%) | 8 (89%) | 8 (100%) | 18 (94%) | *0.09, #0.99, $0.99 |
| Belatacept | 0 (0%) | 1 (11%) | 0 (0%) | 1 (6%) | *0.99, #0.99, $0.99 |
| PRA (%, mean ± SD) | 20.3 ± 29.9 | 35.3 ± 36.4 | 34.6 ± 37.2 | 15.2 ± 29.8 | *0.61, #0.13, $0.20 |
| DSA at TX | |||||
| Positive | 2 (10%) | 2 (22%) | 2 (25%) | 3 (16%) | *0.99, #0.99, $0.27 |
| Negative | 16 (84%) | 7 (78%) | 3 (37.5%) | 16 (84%) | |
| Unknown | 1 (6%) | 0 (0%) | 3 (37.5%) | 0 (0%) | |
| HLA mismatch (A, B, DR) | |||||
| <3/6 | 0 (0%) | 1 (11%) | 0 (0%) | 1 (6%) | *0.99, #0.99, $0.99 |
| ≥3/6 | 14 (74%) | 8 (89%) | 6 (75%) | 18 (94%) | |
| Unknown | 5 (26%) | 0 (0%) | 2 (25%) | 0 (0%) | |
| CMV serostatus | |||||
| D+/R+ | 8 (42%) | 5 (56%) | 3 (38%) | 2 (11%) | *0.07, #0.06, $ <0.01 |
| D+/R– | 1 (6%) | 2 (12%) | 1 (12%) | 4 (21%) | |
| D–/R+ | 4 (21%) | 1 (11%) | 0 (0%) | 5 (26%) | |
| D–/R– | 4 (21%) | 1 (11%) | 0 (0%) | 8 (42%) | |
| Unknown | 2 (10%) | 0 (0%) | 4 (50%) | 0 (0%) | |
| EBV serostatus | |||||
| D+/R+ | 11 (57%) | 7 (78%) | 5 (62%) | 17 (89%) | *0.07, #0.88, $0.37 |
| D+/R– | 1 (6%) | 1 (11%) | 0 (0%) | 2 (11%) | |
| D–/R+ | 2 (10%) | 0 (0%) | 0 (0%) | 0 (0%) | |
| D–/R– | 1 (6%) | 0 (0%) | 0 (0%) | 0 (0%) | |
| Unknown | 4 (21%) | 1 (11%) | 3 (38%) | 0 (0%) | |
| Total ischemia time (minutes, mean ± SD) | 676 ± 634 | 400 ± 466 | 1,191 ± 461 | 349 ± 273 | *0.05, #0.71, $ <0.01 |
| Follow-up (months, mean ± SD) | 16.8 ± 33 | 11.8 ± 10.4 | 37.8 ± 45.4 | 76.1 ± 45.2 | *<0.01, # <0.01, $0.06 |
Data are presented as number (%) of patients, unless otherwise indicated. Variables were compared using the unpaired t-test, Chi-square test or Fischer's exact test, as appropriate. Significance values between groups: *VCA vs. NR, #VCA vs. TCMR, $VCA vs. AMR. AMR, antibody-mediated rejection; ATG, thymoglobulin; BWH, Brigham and Women's Hospital; CNI, calcineurin inhibitor; CMV, cytomegalovirus; D, donor; DSA, donor specific antibody; EBV; Epstein-Barr virus; HLA, human leukocyte antigen; MMF/MPA, mycophenolate mofetil/mycophenolic acid; NR, no-rejection; PRA, panel reactive antibody; R, recipient; SD, standard deviation; TCMR, T-cell mediated rejection; TX, transplantation; VCA, vascularized composite allotransplantation.